Randomized Multicenter Phase II/III Study With Adjuvant Gemcitabine Versus Neoadjuvant / Adjuvant FOLFIRINOX for Resectable Pancreas Carcinoma

NCT02172976 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Resectable Prancreas Carcinoma

Interventions

DRUG: Gemcitabine
DRUG: Oxaliplatin
DRUG: 5-Fluorouracil
DRUG: Irinotecan
DRUG: Natriumfolinate

Sponsor

Krankenhaus Nordwest